Clinic Roundup
• Circadian Technologies Ltd., of Melbourne, Australia, said the FDA approved the investigational new drug application filed by its wholly owned subsidiary, Vegenics Pty Ltd., to initiate clinical trials of VGX-100, a human antibody that acts against the human VEGF-C protein. The Phase I study will evaluate VGX-100 in a variety of late-stage cancers.
To continue reading subscribe now to BioWorld Today
Learn More about BioWorld Today
Already a subscriber? Sign In or Buy now to activate your subscription
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Reproduction, reposting content is strictly prohibited.